Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term chemotherapy. Found 241 abstracts

no pagination
Miknyoczki SJ, Chang H, Klein-Szanto A, Dionne CA, Ruggeri BA. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clinical Cancer Research. 1999 Aug;5(8):2205-12.
Ozols R. Treatment of gynecologic cancer: The US experience. Tumori. 1999 May;85(3):S5-S11.
Smitt MC, Stouffer N, Owen JB, Hoppe RT, Hanks GE. Results of the 1988-1989 patterns of care study process survey for Hodgkin's disease. International Journal of Radiation Oncology Biology Physics. 1999 Jan 15;43(2):335-9.
Stevenson JP, DeMaria D, Sludden J, Kaye SB, Paz-Ares L, Grochow LB, McDonald A, Selinger K, Wissel P, O'Dwyer PJ, Twelves C. Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion. Annals of Oncology. 1999 Mar;10(3):339-44.
Tester WJ, Kim KM, Krigel RL, Bonomi PD, Glick JH, Asbury RF, Kirkwood JM, Blum RH, Schiller JH. A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer - An Eastern Cooperative Oncology Group study (PZ586). Lung Cancer. 1999 Sep;25(3):199-206.
Berlin JD, Propert KJ, Trump D, Wilding G, Hudes G, Glick J, Burch P, Keller A, Loehrer P. 5-fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer - An Eastern Cooperative Oncology Group phase II study (E1889). American Journal of Clinical Oncology-Cancer Clinical Trials. 1998 Apr;21(2):171-6.
Bunn PA, Vokes EE, Langer CJ, Schiller JH. An update on North American randomized studies in non-small cell lung cancer. Seminars in Oncology. 1998 Aug;25(4):2-10.
Freedman GM, Fowble BL, Hanlon AL, Myint MA, Hoffman JP, Sigurdson ER, Eisenberg BL, Goldstein LJ, Fein DA. A close or positive margin after mastectomy is not an indication for chest wall irradiation except in women aged fifty or younger. International Journal of Radiation Oncology Biology Physics. 1998 Jun;41(3):599-605.
Langer CJ, Calvert P, Ozols RF. Gemcitabine and carboplatin in combination: Phase I and phase II studies. Seminars in Oncology. 1998 Aug;25(4):51-4.
Langer CJ, Schaebler D, Sauter E, DeMaria D, Johnson C, Reilly DM, Clark J, Leighton J, Aks C, Litwin S, Ridge JA. Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck. 1998 Aug;20(5):385-91.
Morgan AS, Sanderson PE, Borch RF, Tew KD, Niitsu Y, Takayama T, Von Hoff DD, Izbicka E, Mangold G, Paul C, Broberg U, Mannervik B, Henner WD, Kauvar LM. Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase. Cancer Research. 1998 Jun 15;58(12):2568-75.
Movsas B, Hanlon AL, Lanciano R, Scher RM, Weiner LM, Sigurdson ER, Hoffman JP, Eisenberg BL, Cooper HS, Provins S, Coia LR. Phase I dose escalating trial of hyperfractionated pre- operative chemoradiation for locally advanced rectal cancer. International Journal of Radiation Oncology Biology Physics. 1998 Aug;42(1):43-50.
Paz-Ares L, Kunka R, DeMaria D, Cassidy J, Alden M, Beranek P, Kaye S, Littlefield D, Reilly D, Depee S, Wissel P, Twelves C, O'Dwyer P. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion. British Journal of Cancer. 1998 Nov;78(10):1329-36.
Radjendirane V, Joseph P, Lee YH, Kimura S, Klein-Szanto AJ, Gonzalez FJ, Jaiswal AK. Disruption of the DT diaphorase (NQ01) gene in mice leads to increased menadione toxicity. Journal of Biological Chemistry. 1998 Mar 27;273(13):7382-9.
Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, Fischbach AJ, Curran WJ. Validation and predictive power of radiation therapy oncology group (RTOG) recursive partitioning analysis classes for malignant glioma patients: A report using rtog 90-06. International Journal of Radiation Oncology Biology Physics. 1998 Jan;40(1):51-5.
Witte RS, Ryan LM, Schutt AJ, Carbone PP, Engstrom PF. PALA versus streptozotocin, doxorubicin, and MeCCNU in the treatment of patients with advanced pancreatic carcinoma. Investigational New Drugs. 1998 Jan;16(4):315-8.
Fowble B. Postmastectomy radiation - A modest benefit prevails for high risk patients. Cancer. 1997 Mar 15;79(6):1061-6.
KupczykSubotkowska L, Siahaan TJ, Basile AS, Friedman HS, Higgins PE, Song D, Gallo JM. Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand melphalan conjugate. Journal of medicinal chemistry. 1997 May 23;40(11):1726-30.
Langer CJ. The emerging role of paclitaxel and carboplatin in non-small cell lung carcinoma. In: Updates in Advances in Lung Cancer. 1997. p. 73-90.
Langer CJ, Movsas B, Hudes R, Schol J, Keenan E, Kilpatrick D, Yeung C, Curran W. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: Report of Fox Chase Cancer Center Study 94-001. Seminars in Oncology. 1997 Aug;24(4):89-95.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term chemotherapy

chemotherapy cancer cisplatin trial 5-fluorouracil randomized trial leucovorin therapy radiotherapy cell-lines topotecan GG211 infusion phase-i mastectomy oncology-group mitomycin-c continuous infusion 3-hour radiation-therapy p53 camptothecin analogues expression carcinoma phase-ii trial adjuvant postoperative radiotherapy doxorubicin alkylating-agents survival induction positive breast-cancer clinical-trial phase-ii combination bcnu binding-sites axillary beta-interferon drug- resistant bis-chlorethyl nitrosourea cyto-toxicity brain-tumors validation human ovarian-cancer downstaging Hodgkin's postoperative phase I ifosfamide fam recursive partitioning analysis depletion taxol plus carboplatin southwest-oncology-group phase I trial treatment cyclophosphamide rhabdomyosarcoma xenograft gi147211 carboplatin adenocarcinoma interleukin-2 leukemic-cells modified radical-mastectomy sequence pancreatic carcinoma PALA adriamycin colorectal-carcinoma surgery combination immunotherapy prostate cancer gst-pi-gene polymorphism carmustine buthionine sulfoximine dose intensity camptothecin inhibitor hyperfractionated radiation-therapy young women cell lung-cancer nad(p)h-menadione oxidoreductase breast cancer resistance GI147211 pre-operative therapy nodes radiation- alpha cdna survival-time interferon modulation glutathione pharmacodynamics growth-factor receptor 100880 recurrent gliomas cooperative-oncology-group tumors localization advanced squamous cell carcinoma of the age breast-cancer patients xenografts preoperative radiation-therapy leukemia group-b recurrence paclitaxel resectable adenocarcinoma killer-cells recombinant interleukin-2 enhanced expression recombinant interferon alpha rectal cancer hyperfractionated radiation- rat continuous-infusion 5-fluorouracil topoisomerase I inhibitors protein relapse nsc- etoposide streptozotocin fluorouracil non-small cell lung cancer metabolizing-enzymes rectosigmoid carcinoma aspartate-transcarbamylase camptothecin analogs vinblastine regional recurrence margins progress anti-cancer drugs pharmacokinetics methotrexate radiation oncology head and neck MeCCNU fluorouracil infusion radiation quality prednisone overexpression antioxidant mutagenicity
Last updated on Thursday, June 04, 2020